Document Detail

Objective response of multiple myeloma to cyclosporin A.
MedLine Citation:
PMID:  7696923     Owner:  NLM     Status:  MEDLINE    
Two patients with advanced multiple myeloma were treated with oral low-dose cyclosporin A. one without other therapy and one in conjunction with chemotherapy to which the patient had been previously unresponsive. Both patients had objective laboratory and clinical responses. In the patient treated with cyclosporin A alone, decreasing serum IL-6 and beta-2-microglobulin levels fell as the clinical response evolved. Cyclosporin A deserves further evaluation in the therapy of multiple myeloma.
P H Wiernik; J P Dutcher; A N Leaf; Z Liao; E Paietta; D L Rosenstreich
Related Documents :
81273 - The enhancing effect of multiple sclerosis brain homogenates on the active e rosette fo...
1176993 - Profile of multiple sclerosis in the bombay region. on the basis of critical clinical a...
2818463 - Clinical social work and obsessive compulsive disorder. a single-subject investigation.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  16     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  1994 Dec 
Date Detail:
Created Date:  1995-05-04     Completed Date:  1995-05-04     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  167-70     Citation Subset:  IM    
Department of Oncology and Medicine, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclosporine / administration & dosage,  therapeutic use*
Doxorubicin / administration & dosage
Middle Aged
Multiple Myeloma / drug therapy*
Vincristine / administration & dosage
Grant Support
Reg. No./Substance:
0/VAD protocol; 23214-92-8/Doxorubicin; 50-02-2/Dexamethasone; 57-22-7/Vincristine; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Growth of primary human acute lymphoblastic and myeloblastic leukemia in SCID mice.
Next Document:  Double P53 point mutation in extramedullary blast crisis of chronic myelogenous leukemia.